HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The cut-off value for HOMA-IR discriminating the insulin resistance based on the SHBG level in women with polycystic ovary syndrome.

AbstractIntroduction:
The study aimed to estimate the cut-off value for homeostatic model assessment for insulin resistance (HOMA-IR) discriminating the insulin resistance based on the sex hormones binding globulin (SHBG) level in women with polycystic ovary syndrome (PCOS).
Materials and methods:
Data from medical records of 854 Caucasian women diagnosed with PCOS were analyzed. Anthropometric data, fasting plasma glucose, insulin and SHBG levels were measured. HOMA-IR was calculated with a standard formula. The cut-off value was calculated using receiver-operating characteristics.
Results:
Circulating SHBG levels below the normal range (26.1 nmol/L) were found in 25.4% of study participants. This subgroup had a significantly higher BMI, fasting glucose and insulin concentrations and HOMA-IR values. Empirical optimal cut-off values for HOMA-IR corresponding to low SHBG levels was ≥2.1 [area under the curve (AUC) 0.73, accuracy 0.65, sensitivity 72.3%, specificity 63.1%, positive predictive value (PPV) 40.0%, negative predictive value (NPV) 87.0%].
Conclusions:
Our study suggests that the cut-off point for HOMA-IR discriminating the insulin resistance based on the SHBG level, in young Caucasian women with polycystic ovary syndrome is 2.1, and is consistent with the cut-off value adopted by the European Group for the Study of Insulin Resistance (above 2.0).
AuthorsAleksandra Biernacka-Bartnik, Piotr Kocełak, Aleksander Jerzy Owczarek, Piotr Stanisław Choręza, Leszek Markuszewski, Paweł Madej, Monika Puzianowska-Kuźnicka, Jerzy Chudek, Magdalena Olszanecka-Glinianowicz
JournalFrontiers in medicine (Front Med (Lausanne)) Vol. 10 Pg. 1100547 ( 2023) ISSN: 2296-858X [Print] Switzerland
PMID36968815 (Publication Type: Journal Article)
CopyrightCopyright © 2023 Biernacka-Bartnik, Kocełak, Owczarek, Choręza, Markuszewski, Madej, Puzianowska-Kuźnicka, Chudek and Olszanecka-Glinianowicz.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: